Despite some concerns about increased risk of heart problems, an FDA advisory committee recommended approval of Pargluva, a new drug that helps control blood sugar levels as well as cholesterol in Type II diabetes patients. The noninsulin treatment was developed by Bristol-Myers Squibb and Merck, and the two firms promised to conduct extensive monitoring of patients to ensure it does not cause long-term problems.

Full Story:

Related Summaries